Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey

The stock of Gland Pharma is up 56 per cent over its initial public offering (IPO) price on expectations that its expertise in the injectables space, a clean regulatory track record, and new launches will help sustain 25 per cent-plus growth rates over the next couple of years. India’s largest pharma IPO was listed last month and has gained 29 per cent since then. 

Among the reasons for investors being bullish about the company is the growth prospects over the near-to-medium term. After posting 21 per cent sales growth over the FY17-20 period, analysts, such as Nikhil Mathur of Ambit Capital,